Compugen

Compugen CapEx/D&A

CapEx to Depreciation Ratio of Compugen (CGEN) as of Oct 29, 2026.

CapEx/D&A

-

Last updated:

CapEx to Depreciation Ratio of Compugen is 2026 - . CapEx to Depreciation Ratio of Compugen was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Compugen Stock analysis

What does Compugen do? Compugen Ltd is an Israeli biotechnology company focused on the development of therapeutics and diagnostic products. It was founded in 1993 and is headquartered in Tel Aviv. Compugen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Compugen stock

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio Compugen since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's Compugen with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Compugen

All Key Metrics — Compugen